Company intelligence / Profile preview

Ostara

St. Louis, Missouri, USA

Ownership: Private
Development stage: Other

Overview

Ostara Therapeutics was a clinical-stage biopharmaceutical company primarily focused on developing treatments for women's reproductive health, specifically the prevention of preterm birth. The company was founded by former executives of Lumara Health (formerly KV Pharmaceutical) following its acquisition by AMAG Pharmaceuticals. Its lead candidate, OT-101, was a subcutaneous formulation of 17-alpha-hydroxyprogesterone caproate (17-OHPC) designed to improve upon existing therapies like Makena. Despite its initial promise in addressing a significant unmet need in neonatal health, the company has become inactive following regulatory shifts and the eventual withdrawal of 17-OHPC from the market due to efficacy concerns in larger trials.

Therapeutic areas: Women's Health
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Ostara.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ostara.

Explore the full profile